The drug remains likely to get approval in Europe, but for now stuck in fourth-line treatment. The company’s pipeline lacks other near-term catalysts.
Deciphera Pharmaceuticals, Inc.’s Qinlock (ripretinib) is stuck in the later lines of gastrointestinal stromal tumor (GIST) treatment for the foreseeable future following the failure of a Phase III trial to bring it into earlier lines, while the biotech itself looks set to enter a lull for a while in terms of pipeline catalysts.
The company announced topline results on 5 November from the 453-patient Phase III INTRIGUE study comparing Qinlock against Pfizer...
J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.
The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.
US green light will further expand sales of the prostate cancer blockbuster.
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.
The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.
US green light will further expand sales of the prostate cancer blockbuster.
